A pediatric and adult neurointerventionalist with subspecialty training in radiology, pediatric radiology, neuroradiology and endovascular surgical neuroradiology, Mesha Martinez, MD is Founder and Director of Pediatric Neurointerventional Radiology Program at Indiana University School of Medicine. Her research interests include pediatric neurological and vascular diseases and image guided neurointerventions. She is a doting wife and mother, a patient champion, and a strong advocate for health equity and minority leadership in medicine.
Moleen (Molly) Madziva Taitt, PhD is Vice President of Global Clinical Affairs for Viz.ai. An electrical, computer and software engineer, she established the Viz clinical research program that consists of scientists and operations personnel dedicated to researching the role of AI in care coordination. Previously at Abbott, she researched implantable neuromodulation devices and prior to that at Angelmed, her work led to the first ever FDA approval of an implantable cardiac monitor that warns patients of a suspected myocardial infarction. Born and raised in Zimbabwe, and now living in Southern California, Molly is a voice for diversity, equity and inclusion in shaping teams and inspiring project strategy.
Toni Prince, Ph.D., is Senior Manager of Product Marketing at Viz.ai. Having her grandmother, Elain Russell, pass away in 2000 from Stage 4 colon cancer opened Toni’s eyes to the disparities in healthcare, and she has since dedicated her life to working for meaningful change. Originally from Jamaica, she is an active planning member of Diversity by Doing (DxD), founded in partnership between Stanford Byers Center for Biodesign and Fogarty Innovation to enhance diversity, inclusion, and equity within medtech companies. She is also a member of Forbes BLK. Toni strives to amplify the voices of other thought leaders focused on AI’s role in health equity.
It’s critical that we address these examples of institutionalized bias and racism in how we approach clinical trials for drugs and devices. While it’s a daunting task, the path forward is surprisingly clear, and AI can be instrumental in the next step of overcoming unconscious biases inherent in clinical trial processes.